AI, Data Science & Cloud Certificates from Google, IBM & Meta — 40% Off
One plan covers every Professional Certificate on Coursera. 40% off Coursera Plus Annual.
Unlock All Certificates
Learn about the latest prostate cancer clinical trial results and treatment advances from the 2025 European Society for Medical Oncology (ESMO) conference in this 26-minute medical education video. Discover key findings from three pivotal randomized phase III trials that are reshaping prostate cancer treatment protocols. Explore the PSMA Addition trial results showing how LuPSMA-617 combined with androgen receptor pathway inhibitors (ARPI) and androgen deprivation therapy (ADT) improves radiographic progression-free survival compared to standard abiraterone plus ADT in first-line metastatic castration-sensitive prostate cancer. Examine the CAPItello-281 study demonstrating that capivasertib, an AKT inhibitor, when added to abiraterone and ADT, significantly improves outcomes in PTEN-deficient metastatic castration-sensitive prostate cancer patients. Review the EMBARK trial findings revealing how enzalutamide combined with ADT enhances metastasis-free survival and overall survival in high-risk biochemical relapse cases detected through conventional imaging. Gain insights into radioligand therapy applications, targeted treatment approaches for specific genetic markers, and evidence-based strategies for managing different stages of prostate cancer progression.
